Acetyl-CoA carboxylase inhibitor increases LDL-apoB production rate in NASH with cirrhosis: prevention by fenofibrate

Treatment with acetyl-CoA carboxylase inhibitors (ACCi) in nonalcoholic steatohepatitis (NASH) may increase plasma triglycerides (TGs), with variable changes in apoB concentrations. ACC is rate limiting in de novo lipogenesis and regulates fatty acid oxidation, making it an attractive therapeutic ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Dandan, Mohamad, Han, Julia, Mann, Sabrina, Kim, Rachael, Li, Kelvin, Mohammed, Hussein, Chuang, Jen-Chieh, Zhu, Kaiyi, Billin, Andrew N., Huss, Ryan S., Chung, Chuhan, Myers, Robert P., Hellerstein, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2023
Materias:
Patient-oriented and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017426/
https://www.ncbi.nlm.nih.gov/pubmed/36737040
http://dx.doi.org/10.1016/j.jlr.2023.100339

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017426/
https://www.ncbi.nlm.nih.gov/pubmed/36737040
http://dx.doi.org/10.1016/j.jlr.2023.100339

Ejemplares similares